Stock info Transgene | Filter  Basic-Info

Transgene

The past year was a profitable year for the Transgene investors

Over the period from December 2015 till December 2016 the stock gained around 13 percent. Over the past 5 years Transgene' stock lost at around 61 percent in value. Transgene's revenues between 2011 and 2015 were far from constant and moved between 13,06 million euros and 9,57 million euros. The net results between 2011 and 2015 were far from constant and fluctuated between -43,39 million euros and -30,36 million euros.

Transgene is mostly active in the biotech sector. Over the past 10 years the global biotech companies gained around 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

The French company didn't pay out any dividends (in the past 5 years). Over the past 5 years the company raised it's dividends each year. Based on the raising dividend payments Transgene can be seen as a kind of dividend aristocrat.

Healthy financed: not so much debt Transgene

At the end of 2015 the French company had a balance sheet of around 100,87 million euros. The total debt of the biotech company was at the end of 2015 74,32 million euros, which equals around 73,68 percent of the total balance sheet.

At the end of 2015 the French company had around 38,55 million stocks listed.

All the annual reports of Transgene are available here. More information about Transgene can be found it's website. .